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Abstract
The clinical response of sepsis to a systemic inflammatory infection may be complicated by
disseminated intravascular coagulation or DIC. In order to experimentally study the syndrome of
DIC, we aimed for a severe sepsis model complicated by disseminated coagulation. Most -
simplified- experimental models describing coagulation abnormalities as a consequence of sepsis
are based on single dose endotoxemia. The so called-Shwartzman reaction contrarily, is elicited by
a low dose endotoxin priming followed by an LPS challenge and is characterized by pathological
manifestations that represent the syndrome of DIC. In order to investigate whether the
Shwartzman reaction is superior to a single endotoxin challenge as a model for sepsis-induced DIC
and to determine what the pathological effect is of an encounter of low endotoxin prior to an LPS
challenge, we undertook the present study.
In this study we demonstrate that low-dose endotoxin priming prior to an LPS challenge in the
Shwartzman reaction is accountable for micro-vascular thrombosis in lung and liver and subsequent
(multi-) organ failure, not observed after a single-dose endotoxin challenge, which indicates that the
Shwartzman reaction is well suited-model to study sepsis-induced DIC adversities. Remarkably,
only minor differences in the innate immune response were established between the single-dose
endotoxin challenge and the Shwartzman reaction.
Background
Severe bacterial infections may pass into the bloodstream
where endotoxin or lipopolysaccharide (LPS) present on
the outer membranes of (gram-negative) bacteria can pro-
voke a systemic inflammatory response syndrome. The
term sepsis is used to identify the continuum of the clini-
cal response to such a systemic infection and sepsis may
progress to severe sepsis or septic shock when additional
organ dysfunction and hypoperfusion develop [1]. The
initial manifestation of the infection is overwhelming
inflammation, known as the innate immune response.
Furthermore, severe sepsis is complicated by disseminated
intravascular coagulation (DIC), a syndrome character-
ized by micro-vascular thrombosis and (multi-) organ
failure consequently increasing mortality rate [2].
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Although a contributory relation between intravascular
deposition of fibrin, as a result of the systemic activation
of coagulation, and the development of organ damage is
not firmly established, anticoagulant strategies are
believed to benefit the condition of DIC [2,3]. Thus far,
the restoration of the anti-coagulant protein C pathway by
the infusion of recombinant human activated protein C
(APC) is the only treatment strategy proven to improve
sepsis-related mortality [4]. Interestingly, sub-group anal-
ysis indicated that patients who were classified as having
DIC, (according to the DIC scoring system of the ISTH
[5]) had a relatively greater benefit of APC treatment than
patients who did not have overt DIC [6] which under-
scores the importance of coagulation derangement in the
pathogenesis of severe sepsis/DIC. Large-scale, multi-cen-
tre, randomized controlled trials aimed at the restoration
of the antithrombin (ATIII) [7] and tissue factor pathway
inhibitor (TFPI) [8,9] anticoagulant pathways however,
did not demonstrate a significant reduction in mortality
in patients with sepsis, suggesting that targeting the aggra-
vated coagulation response is not sufficient and addi-
tional strategies should be considered.
In order to study the pathogenic characteristics during the
sepsis-induced DIC phenomenon we aimed for a murine
endotoxin-induced model, with consequential coagula-
tion abnormalities resembling (human) DIC. Endotox-
emia models by a single LPS infusion are often used as a
representative for sepsis as they mimic the initial innate
immune response [10-12]. Although coagulation abnor-
malities have been described in such models [10,11], the
Shwartzman reaction might be a better model projecting
severe sepsis complicated by DIC [13].
The Shwartzman reaction can be elicited in experimental
(animal) models by two consecutive injections of endo-
toxin and is characterized by platelet aggregation, vascular
occlusion, inhibition of fibrinolysis, neutrophil accumu-
lation, endothelial injury and variable degrees of apopto-
sis and necrosis in the microvasculature [14-17]. In order
to investigate whether the Shwartzman reaction is supe-
rior to a single endotoxin challenge as a model for sepsis-
induced DIC and to determine what the pathological
effect is of an encounter of low endotoxin prior to an LPS
challenge, we undertook the present study.
Materials and methods
Animals
10 Week old, female C57Bl/6 mice were purchased from
Charles River (Someren, the Netherlands). All mice were
maintained at the animal care facility at the Academic
Medical Center according to institutional guidelines. Ani-
mal procedures were carried out in compliance with the
Institutional Standards for Humane Care and Use of Lab-
oratory Animals. The Animal Care and Use Committee of
the Academic Medical Centre (Amsterdam, the Nether-
lands) approved all experiments.
Experimental design
Mice were subjected to two consecutive injections; a low
dose endotoxin priming injection of 5 μg Serratia marces-
cens LPS (Sigma-Aldrich, St. Louis, MO)(in 40 μl) or ster-
ile saline control (no-priming) was given in the foot
(intradermally) and was followed 24 h later by an intrave-
nous LPS challenge (300 μg Serratia marcescens LPS)(in
100 μl) [18]. Mice receiving two endotoxin injections will
develop a Shwartzman reaction. No-priming controls rep-
resent a single-dose endotoxemia model.
Mice were sacrificed at baseline levels (t = -24 h), 24 hours
after priming (t = 0 h), 2 hours after challenge (t = 2 h)
and 6 hours after challenge (t = 6 h). Each group con-
tained 8 mice.
Cytokine chemokine assay
IL-6, IL1β, KC and TNFα were measured using the Bio-Rad
Bioplex system following manufacturer's instructions. In
short, dyed beads conjugated with monoclonal antibod-
ies are allowed to react with sample and a secondary
detection antibody. Bio-Plex array reader illuminates the
dyed beads and the distinct fluorescent signature allows
the identification of each bead. A green laser in the array
reader simultaneously excites the fluorescent reporter tag
bound to the detection antibody in the assay. The amount
of green fluorescence is proportional to the amount of
analyte captured in the immunoassay. Extrapolating to a
standard curve allows quantification of each analyte in the
sample.
Histological examination
Tissue (lung, liver and kidney) sections were fixed in 10%
buffered formalin and embedded in paraffin; 4 μm thick
sections were stained with haemotoxylin and eosin.
Number of thrombi in liver and lung and necrotic areas in
liver were scored for ten microscopic fields at a magnifica-
tion of 25 ×.
Enzyme assay
Creatinine and liver enzymes (ASAT/ALAT) in plasma (1:5
dilution in 0.9% sterile saline) were determined with
commercially available kits (Sigma) using a Hitachi ana-
lyzer (Boehringer Mannheim, Mannheim, Germany)
according to manufacturer's instructions.
Statistical analysis
Statistical analyses were conducted using GraphPad Prism
version 3.00, Graphpad software (San Diego, CA). Data
are expressed as means ± SE. Comparison between two
groups was analyzed using two-tailed Mann-Whitney U
tests.Thrombosis Journal 2006, 4:13 http://www.thrombosisjournal.com/content/4/1/13
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Results
Effect of low endotoxin priming on the innate immune 
response
Intravenous LPS infusion primarily results in an inflam-
matory reaction that reflects the innate immune response.
Therefore we analyzed the inflammatory markers IL-1β,
KC (neutrophil chemotactic protein), IL-6, TNFα, and IL-
10 in plasma of mice subjected to a single intravenous LPS
challenge (no-priming) or a double hit Shwartzman reac-
tion (+24 h low dose endotoxin priming).
Two hours after LPS challenge IL-1β levels are notably
increased in mice that were subjected to 24 hours of low
dose endotoxin priming compared to the non-primed
mice (p < .001) (fig 1a), the difference however, becomes
less pronounced 6 hours after the LPS challenge (ns).
Contrarily, KC and IL-6 levels are not evidently affected by
24 hours of low dose priming (fig 1b and 1c).
The inflammatory mediators, IL-6, TNFα and IL-10 are
transiently increased in response to the LPS challenge.
TNFα levels are significantly (p < .01) lower in mice sub-
jected to low dose endotoxin priming compared to the
non-primed mice 2 hours after LPS challenge (fig 1d); this
effect nevertheless disappears in time. The level of the
anti-inflammatory cytokine IL-10 is slightly but signifi-
cantly (p < .05) lower in the non-primed mice compared
to the mice who did receive the priming injection 6 hours
after LPS challenge (fig 1e). These results indicate that 24
hours of low dose endotoxin priming has minor effects on
the innate immune response towards an LPS challenge.
Low dose endotoxin priming results in micro-vascular 
thrombosis
The syndrome of DIC is characterized by coagulation
abnormalities featured by micro-vascular thrombosis in
target organs. The Shwartzman reaction is proposed to
represent an endotoxin-induced model of DIC. Therefore,
we determined the effect of low dose endotoxin priming
on the formation of micro-vascular thrombi. Figure 2
demonstrates that LPS challenge induces a significant
increase in the number of thrombi formed in the lung (fig
2a) and liver (fig 2b) of mice that were subjected to low
dose endotoxin priming. Contrarily, hardly any thrombi
formation is observed in mice not subjected to low dose
endotoxin prior to the LPS challenge (difference 24 h low
dose priming compared to non-primed mice 6 h after LPS
challenge for liver and lung; p < .001). Interestingly, some
micro thrombi are already formed after 24 h of low endo-
toxin priming, before LPS challenge was infused. Apart
from isolated inflammatory foci, HE-stained histological
sections from kidneys seemed normal in mice subjected
to the Shwartzman reaction or a single-dose LPS challenge
(not shown).
(Ischemia-induced) organ damage
Histological examination furthermore displayed signifi-
cant hepatic necrosis in mice subjected to low dose endo-
toxin priming; contrarily, necrotic area's in livers of non-
primed mice were absent (figure 3; p < .001, 6 h after LPS
challenge). In addition to these microscopic differences
we also observed macroscopic variability between primed
and non-primed mice. Livers of mice exposed to 24 hours
of low dose endotoxin priming preceding the LPS chal-
lenge exposed a differential degree of ischemic necrosis on
the liver surface (not shown). These spots were absent on
the surface of the livers of non-primed mice. Figure 3
demonstrates that low dose endotoxin priming prior to an
LPS challenge results in ischemic necrosis. Besides coagu-
lation abnormalities and ischemia induced necrosis, DIC
may be complicated by (multi-) organ failure and death.
Detection of organ damage markers in plasma of mice
challenged with LPS demonstrates that low endotoxin
priming is critical in the development of both kidney and
liver failure. Figure 4a demonstrates that creatinine, a
marker for renal failure, is significantly (p < .05) increased
6 hours after LPS challenge, in mice that were previously
subjected to low dose endotoxin priming compared to
non-primed mice. Creatinine levels in non-primed mice
contrarily where not elevated in response to LPS chal-
lenge.
In addition, transaminases ASAT and ALAT were highly
increased due to the endotoxin priming (fig 4b+c). LPS
challenge in non-primed mice also results in a significant
increase of the transaminases 6 hours after LPS challenge
compared to baseline (fig 4b, ASAT p < .001: fig 3c, ALAT
p < 05 ;), the effect, however, was obviously smaller com-
pared to mice that we exposed to the endotoxin priming.
These results indicate that low endotoxin priming makes
mice more susceptible to a subsequent LPS challenge,
resulting in aggravated kidney and liver damage.
Discussion
The clinical response of sepsis to a systemic inflammatory
infection may be complicated by DIC. The syndrome of
DIC increases mortality rate and patients with DIC may
even respond differently to therapeutic treatment com-
pared to septic patients not hindered by DIC [6]. In order
to experimentally study the syndrome of DIC, we aimed
for a severe sepsis model complicated by DIC. The
Shwartzman reaction has been described as a two-hit ani-
mal-model representing DIC [13]. However, most experi-
mental models describing coagulation abnormalities in
mice as a consequence of sepsis are based on single dose
endotoxemia or live E. coli models. Sustained endotoxin
infusions are also regularly used as models for DIC,
though predominantly in larger animals like rats and rab-
bits [19,20].Thrombosis Journal 2006, 4:13 http://www.thrombosisjournal.com/content/4/1/13
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Systemic innate immune response after LPS challenge Figure 1
Systemic innate immune response after LPS challenge. (a) Represents the effect of low dose endotoxin priming on 
LPS induced IL-1β levels. (b) demonstrates KC levels, and panel (c) (d) and (e) represent respectively IL-6, IL-10 TNFα levels in 
plasma. (mean ± SE)Thrombosis Journal 2006, 4:13 http://www.thrombosisjournal.com/content/4/1/13
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The initial priming reaction in the Shwartzman phenom-
enon is a requisite in order to induce lethality [14,21]. In
this study we reveal that low-dose endotoxin priming
prior to an LPS challenge is accountable for micro-vascu-
lar thrombosis and subsequent (multi-) organ failure,
which suggests an important role for intravascular
thrombi formation contributing to lethality.
Low-dose endotoxin priming, in this study furthermore
prominently induced the leak of transaminase enzymes,
without further aggravation by LPS challenge. Transami-
nase leakage is a characteristic for liver dysfunction and
reflects acute cellular and mitochondrial injury induced
by endotoxin [4,22]. Clinically, secondary liver dysfunc-
tion accounts for the spill-over of bacterial and inflamma-
tory mediators, -frequently- leading to multi-organ failure
and death [4] In line, LPS challenge in our experimental
DIC-model results in augmented hepatic thrombi forma-
tion and subsequent necrosis i.e. liver damage.
The aggravation of the LPS response in the Shwartzman
reaction is distinctive to the endotoxin tolerance phenom-
enon wherein low dose endotoxin exposure confers pro-
tection against LPS-induced lethality. Endotoxin tolerance
is characterized by a markedly reduced immune response
and may complicate the management of critically ill
patients, particularly patients with severe sepsis [23]. Two
phases of endotoxin tolerance have been described: an
early phase associated with augmented cellular activation
and a late phase associated with the development of spe-
cific endotoxin- antibodies. Timing and dosage of low
Hepatic (ischemic) necrosis Figure 3
Hepatic (ischemic) necrosis. Necrotic areas in the liver 
were scored for 10 microscopic fields (25×) using haematox-
ylin and eosin stained sections (mean ± SE)
Thrombi formation in liver and lung Figure 2
Thrombi formation in liver and lung. Formation of (micro-) thrombi after LPS challenge with and without 24 hours of low 
dose endotoxin priming. (a) Represents the number of thrombi in liver. (b) Demonstrates the number of thrombi in 10 micro-
scopic fields (25×) in lung tissue. (mean ± SE)Thrombosis Journal 2006, 4:13 http://www.thrombosisjournal.com/content/4/1/13
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dose endotoxin is critical in endotoxin tolerance [23] as
well as the Shwartzman phenomenon [24], apparently
resulting in divergent responses. In general, endotoxin tol-
erance may be considered a state of a dysregulated immu-
nity decreasing the ability to fight infection. The
Shwartzman phenomenon on the contrary, affects the
coagulatory response aggravating organ dysfunction with
minor effects on innate immune responses.
The time interval and dosage of the priming injection are
crucial determinants for the Shwartzman reaction to occur
[24], the reaction may however also be elicited by two
intravenous injections as it will result in similar tissue
damage [24]. A local intra-dermal injection is however,
easier to manipulate and herein we therefore subjected
the mice to an intra-dermal preparatory injection.
Based on the results obtained from this study we conclude
that the Shwartzman reaction is better suited to study sep-
sis-induced DIC adversities compared to a single intrave-
nous endotoxin challenge. In non-primed mice no
distinct coagulation abnormalities and/or additional
organ dysfunction were observed, suggesting that the
(intravenous) single-dose endotoxin challenge is well-
suited to study the innate inflammatory response not
complicated by DIC.
It should be noted that both endotoxemia models as well
as the Shwartzman reaction are obviously different from
the clinical situation where a variety of complications
occur, these experimental models are thus tentative as a
tool to assess new treatment strategies. Endotoxin-
induced models may however, be considered appropriate
tools to elucidate the underlying pathological mecha-
nisms contributing to sepsis and clotting-related organ
failure.
Conclusion
In this study we demonstrate that low-dose endotoxin
priming prior to an LPS challenge in the Shwartzman reac-
tion is accountable for micro-vascular thrombosis and
subsequent (multi-) organ failure, not observed in a
(intravenous) single-dose endotoxin challenge, which
indicates that the Shwartzman reaction is well suited-
model to study sepsis-induced DIC adversities.
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